MS Views and News Be empowered with MS views and news. To receive The MS BEACON e-Newsletter, CLICK HERE - -

Visit our MS learning channel on YouTube, which provides hundreds of MS educational videos presented by MS Experts from across the USA. Archived here: www.youtube.com/msviewsandnews -- Also please visit our Social media platforms: Facebook, Twitter, and Instagram . Each providing important information for the MS community. Furthermore, scroll down the left side of this blog to learn from the resources and links.

Disclaimer: 'MS Views and News' DOES NOT endorse any products or services found on this blog. It is up to you to seek advice from your healthcare provider. The intent of this blog is to provide information on various medical conditions, medications, treatments, for your personal knowledge and to keep you informed of current health-related issues. It is not a substitute for the advice of your physician. Should you or your family members have any specific medical problem, seek medical care promptly.

~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~


Saturday, June 28, 2008

Multiple Sclerosis Care - The Fundamentals

Obtained from MS Central.com

The Fundamentals of Multiple Sclerosis Care
by Dr. Kantor
Monday, June 23, 2008

There is a lot of talk about research and medical advances in the treatment of multiple sclerosis, but I would like to return to the fundamentals of MS care and how these new treatment options fall into the framework of MS care.


There are three important arms of MS treatment:


1. Disease Modifying Agents - Medications that are used to change the course of MS, but which you may not feel any current effect from (though you may have side effects unfortunately), but are like an insurance policy for the future. There are 5 FDA approved medications for Relapsing forms of MS: Avonex®, Rebif®, Betaseron®, Copaxone® and Tysabri®. Novantrone® is a chemotherapy drug, also FDA approved for worsening relapsing MS or secondary progressive MS.

» Read More


.

No comments: